Evidence map›Paper›PMID 41063901›Full record

ArticleCureus2025

Intraoperative Anaphylaxis to Isosulfan Blue: Recognizing a Rare but Life-Threatening Reaction.

Brianne Falatovich, Makayla Gologram, D'Arcy Duke

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Brianne FalatovichGeneral Surgery, Conemaugh Memorial Medical Center, Johnstown, USA.
Makayla GologramGeneral Surgery, Conemaugh Memorial Medical Center, Johnstown, USA.
D'Arcy DukeBariatric Surgery, Conemaugh Memorial Medical Center, Johnstown, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isosulfan blue injection (Lymphazurin) is a blue dye injection that is commonly used to map lymphatics in lymphangiography and sentinel lymph node biopsies. A 75-year-old male with a history of hyperlipidemia presented after excision of multiple lesions with plastic surgery, revealing melanoma in situ on the patient's scalp and superficial spreading melanoma with 4 mm margins on the right posterior axilla. During what was expected to be a routine procedure, anesthesia informed the operating room that the patient had become abruptly hypotensive, but responded to a one-time dose of peripheral vasopressors. The patient's chest and face were noticed to be erythematous and edematous when the patient was turned to begin the wide local excision. Welts and hives were noticed to be originating from the area where isosulfan blue was injected. The patient did fully recover from the incident with no unfortunate sequelae, but given this likely anaphylactic event, the patient should never again be exposed to isosulfan blue without direct physician care. Most reactions to isosulfan blue occur on first exposure and, despite its misnomer, have little to no relation to sulfa allergies. This case report and literature review critique the uses and indications for isosulfan blue, as well as discuss the hazards and prevention of these potentially critical reactions.

Indexed as

anaphylaxisisosulfan bluelymphaticsmelanomasentinel lymph node biopsy

Identifiers

PMID41063901
PMCPMC12503956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.